Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Generic Entry into DPP-4 Class Poised to Accelerate in 2026
Several DPP-4 inhibitors are emerging as prime targets for additional generic listings in 2026, Jiho has learned, with copycat entries expected to broaden for products such as Januvia/Glactiv (sitagliptin) and Trazenta (linagliptin). According to industry sources, multiple generic makers are…
To read the full story
Related Article
- Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
- 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
- Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
- Vimpat Draws 10 Generic Entrants in December Listing; Forxiga Has Two, but Nipro AG Absent
December 4, 2025
- Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
August 18, 2025
- EquMet, Clenafin See Generic Entry in June Listing
June 12, 2025
- Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
- Japan to Approve EquMet Generics, More Copycats toward June Listing
February 17, 2025
- SGLT2 Inhibitor Forxiga Braced for Generic Entry in 2025
January 14, 2025
- Merck Sues Sawai over Januvia Generics Approved in Japan
October 27, 2023
- Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
August 16, 2023
BUSINESS
- Astellas Tops 2 Trillion Yen in Sales, Gears Up for Post-Xtandi Growth
April 28, 2026
- Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
- Teikoku, Curedisc Ink Japan Deal for Disc Herniation Drug
April 28, 2026
- FRONTEO, Science Tokyo Roll Out AI Drug Discovery Hub
April 28, 2026
- Kyorin to Transfer Generics Unit to Daito-Led JV
April 28, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…